Novel Self-emulsifying Formulation of Curcumin with Improved Dissolution, Antiangiogenic and Anti-inflammatory Activity

REFERENCES

• DK Podolsky. (2002). Inflammatory bowel disease. N Eng J Med. 347:417–429.
   PubMed Web of Science ®Google Scholar
• SB Hanauer. (1996). Inflammatory bowel disease. N Eng J Med.. 334:841–848.
   PubMed Web of Science ®Google Scholar
• AJ Ruby, G Kuttan, KD Babu, KN Rajasekharan, and R Kuttan. (1995). Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94:79–83.
   PubMed Web of Science ®Google Scholar
• AJ Gescher, RA Sharma, and WP Steward. (2001). Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. 2:371–379.
   PubMed Web of Science ®Google Scholar
• RA Sharma, AJ Gescher, and WP Steward. (2005). Curcumin: The story so far. Eur J Cancer. 41:1955–1968.
   PubMed Web of Science ®Google Scholar
• RA Sharma, HR McLelland, KA Hill, and et al (2001). Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7:1894–1900.
   PubMed Web of Science ®Google Scholar
• DS Rao, NC Sekhara, MN Satyanarayana, and M Srinivasan. (1970). Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutrition. 100:1307–1315.
   PubMed Web of Science ®Google Scholar
• C Ramaprasad, and M Sirsi. (1956). Indian medicinal plants: Curcuma longa; in vitro antibacterial activity of curcumin and the essential oil. J Sci Ind Res. 15C:239–241.
   Google Scholar
• HPT Ammon, and MA Wahl. (1991). Pharmacology of Curcuma longa. Planta Med. 57:1–7.
   PubMed Web of Science ®Google Scholar
• L Subramanian, and R Selvam. (1999). Prevention of CCI4-induced hepatotoxicity by aqueous extract of turmeric. Nutra Res. 19:429–441.
   Web of Science ®Google Scholar
• A Ukil, S Maity, S Karmakar, N Datta, JR Vedasiromoni, and PK Das. (2005). Curcumin, the major component of food flavor turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 139 (2):209–218.
   Web of Science ®Google Scholar
• HH Tonnesen, and JV Greenhill. (1992). Studies on curcumin and curcuminoids. XXII. Curcumin as a reducing agent and as a radical scavenger. Int J Pharm. 87:79–87.
   Web of Science ®Google Scholar
• B Wahlstrom, and G Blennow. (1978). A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol. 43:86–92.
   PubMedGoogle Scholar
• MH Pan, TM Huang, and JK Lin. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 27:486–494.
   PubMed Web of Science ®Google Scholar
• GM Holder, JL Plummer, and AJ Ryan. (1978). The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat. Xenobiotica. 8:761–768.
   PubMed Web of Science ®Google Scholar
• CR Ireson, S Orr, DL Jones, and et al (2001). Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit cyclooxygenase-2 expression. Cancer Res. 61:1058–1064.
   PubMed Web of Science ®Google Scholar
• RN Gursoy, and S Benita. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 58:173–182.
   PubMed Web of Science ®Google Scholar
• T Maeda, H Takenaka, Y Yamahira, and T Noguchi. (1979). Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets. J Pharm Sci. 68:1286–1289.
   PubMed Web of Science ®Google Scholar
• Y Chiba, N Kohri, K Iseki, and K Miyazaki. (1991). Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. Chem Pharm Bull. 39:2158–2160.
   PubMed Web of Science ®Google Scholar
• MS Kislalioglu, MA Khan, C Blount, RW Goettsch, and S Bolton. (1991). Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates. J Pharm Sci. 80:799–804.
   PubMed Web of Science ®Google Scholar
• HO Ho, HL Su, T Tsai, and MT Sheu. (1996). The preparation and characterization of solid dispersions on pellets using a fluidized-bed system. Int J Pharm. 139:223–229.
   Web of Science ®Google Scholar
• JR Moyano, MJ Arias, JM Gines, and AM Rabasco. (1997). Dissolution behavior of oxazepam in presence of cyclodextrins-evaluation of oxazepam binary system. Drug Dev Ind Pharm. 23:379–385.
   Web of Science ®Google Scholar
• S Okonogi, T Oguchi, E Yonemochi, S Puttipipatkhachorn, and K Yamamoto. (1997). Improved dissolution of ofloxacin via solid dispersion. Int J Pharm. 156:175–180.
   Web of Science ®Google Scholar
• SD Yoo, SH Lee, E Kang, and et al (2000). Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev Ind Pharm. 26 (1):27–34.
   PubMed Web of Science ®Google Scholar
• CK Kim, YJ Cho, and ZG Gao. (2001). Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J Control Release. 70:149–155.
   PubMed Web of Science ®Google Scholar
• CW Pouton. (1997). Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 25:47–58.
   Web of Science ®Google Scholar
• RN Gursoy, and S Benita. (2004). Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 58:173–182.
   PubMed Web of Science ®Google Scholar
• J Folkman, and M Klagsbrun. (1987). Angiogenetic factors. Science. 235:442–447.
   PubMed Web of Science ®Google Scholar
• MA Schubert, and CC Muller-Goymann. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm. 55:125–131.
   PubMed Web of Science ®Google Scholar
• AA Attama, and MO Nkemnele. (2005). In vitro evaluation of drug release from self micro-emulsifying drug delivery systems using a biodegradable homo-lipid from Capra hircus. Int J Pharm. 304:4–10.
   PubMed Web of Science ®Google Scholar
• M Presta, M Belleri, A Vacca, and D Ribatti. (2002). Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia. 16:1490–1499.
   PubMed Web of Science ®Google Scholar
• EG Anupama, M Belakavadi, DA Venkatesh, D Marme, and BP Salimatha. (2002). Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem and Biophys Res Com. 297:934–942.
   PubMed Web of Science ®Google Scholar
• J Vilaseca, A Salas, F Guarner, R Rodinguez, M Martinez, and JR Malagelada. (1990). Dietary fish oil reduces progression of chronic inflammatory lesions in rat model of granutomatous colitis. Gut. 31:539–544.
   PubMed Web of Science ®Google Scholar
• JL Wallace, WK Mac Naughton, GP Morris, and PL Beck. (1989). Inhibition of leucotriene synthesis markedly accelerates healing in rat model of inflammatory bowel disease. Gastroenterology. 96:29–36.
   PubMed Web of Science ®Google Scholar
• SD Skaper, M Pollock, and L Facci. (2001). Mast cells differentially express and release active high molecular weight neurotrophins. Mol Brain Res. 97:177–185.
   PubMedGoogle Scholar
• S Jose, and PK Kulkarni. (2002). Self emulsifying drug delivery systems (SEDDS): a review. Indian J Pharm Ed. 36:1–7.
   Google Scholar
• A Paradkar, AA Ambike, BK Jadhav, and KR Mahadik. (2004). Characterization of curcumin–PVP solid dispersion obtained by spray drying. Int J Pharm. 271:281–286.
   PubMed Web of Science ®Google Scholar
• HS Cooper, S Murthy, K Kido, H Yoshitake, and A Flanigan. (2000). Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis. 21:757–768.
   PubMed Web of Science ®Google Scholar